News & Events

< Back to News Overview

Endoluminal Sciences enters into a license agreement with Symetis

27 / 09 / 2013

Sydney, Australia, September 26, 2013 – Endoluminal Sciences Pty Ltd, an Australian medical device company focused on developing technologies for next generation transcatheter treatment of structural heart disease, announced today that it has entered into a license agreement with a Swiss company, Symetis SA, to grant rights to its active anti-paravalvular leak technology for the transcatheter aortic valve implantation (TAVI) field.


TAVI has been developed as a means to treat aortic valve disease using a minimally invasive approach. Symetis has developed ACURATE TA and ACURATE TF products for the estimated $2 billion TAVI market. Symetis will incorporate Endoluminal Sciences’ active anti-paravalvular leak technology into its ACURATE TAVI™ product line with the goal of continuing to reduce paravalvular leak in patients undergoing TAVI procedures.


Paravalvular leak (PVL) occurs in the majority of patients undergoing TAVI and is a key determinant of increased post-procedural mortality. Since the publication of Kodali et al. in 2012, reduction of PVL has been identified as the main challenge to unleashing the full potential of the TAVI market. Several companies in the TAVI market already have programs to partially address this challenge using various passive solutions. This includes Symetis’ “Self-Sealing” technology that has been designed into the ACURATE TAVI™ products and has contributed to strong clinical results. Endoluminal Sciences has developed a unique solution to actively reduce PVL in transcatheter heart valve prostheses based upon the company’s proprietary swelling polymer and membrane technology.


According to Dr. Raj Makkar, MD (Cedars Sinai, Los Angeles), a member of Endoluminal Sciences’ clinical advisory team: “Reducing paravalvular leak is critical for long-term success of TAVI. Endoluminal Sciences’ active anti-paravalvular leak technology is a novel solution to this problem.”


“By combining Symetis’ Self-Sealing TAVI design with Endoluminal Sciences’ active anti-PVL technology, Symetis is establishing its ZeroLeak™ vision: offering superior clinical outcomes by eliminating relevant PVL for all patients, while maintaining ACURATE’s reputation for uncomplicated valve delivery,” said Jacques Essinger, Ph.D, CEO of Symetis.


Stéphane Delaloye, VP R&D at Symetis added: “Our initial in-vitro evaluation confirmed that Endoluminal Sciences’ sealing technology has the potential to address PVL in the most challenging calcification patterns. Mounting this novel technology onto our ACURATE TAVI™ platform will allow us to further reduce PVL for the benefit of all patients.”


Ashish Mitra, CEO & Founder of Endoluminal Sciences said, “We are very excited to partner with Symetis and to be part of the foundation of a unique 3rd generation of TAVI devices that will improve patient outcomes. We believe the combination of ACURATE TAVI™ products and Endoluminal Sciences’ active anti-PVL technology will prove to be a winning combination.”


About Endoluminal Sciences

Endoluminal Sciences is an Australian company committed to the development of novel, platform technologies to dramatically enhance the clinical performance of endovascular prostheses. While its novel technologies are foreseen to have applications in a range of vascular disease states, the company’s immediate focus is the transcatheter treatment of structural heart disease. Endoluminal Sciences is financed by GBS Venture Partners, Australia’s leading healthcare venture capital firm and Reidsdale Investments.


About Symetis

Symetis SA is a privately-owned Swiss company developing innovative, minimally invasive heart valve replacement solutions ( The company’s products, ACURATE TA™ and ACURATE TF™, are based on proprietary geometry and delivery technologies and are well positioned to target the estimated $2 billion TAVI market. Based in Lausanne, the company is financed by leading European venture capital firms, including Truffle Capital, Novartis Venture Fund, Wellington Partners, Aravis Venture, Vinci Capital, Banexi Ventures, Endeavour Vision, NBGI Ventures and BiomedInvest.


For further information, please contact:

Ashish Mitra

Chief Executive Officer